Brickell Biotech, Inc.
(NASDAQ : BBI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -2.62%35.670.9%$908.03m
JNJJohnson & Johnson -2.37%145.640.7%$907.17m
MRKMerck & Co., Inc. -3.55%82.760.7%$683.79m
ABBVAbbVie, Inc. -2.56%87.801.9%$646.25m
BMYBristol-Myers Squibb Co. -2.80%57.611.0%$554.19m
LLYEli Lilly & Co. -1.77%151.441.1%$542.25m
AZNAstraZeneca Plc -2.16%55.231.2%$247.58m
NVSNovartis AG -2.11%89.020.2%$162.99m
PRNBPrincipia Biopharma, Inc. -0.30%99.970.0%$117.71m
GSKGlaxoSmithKline Plc -2.85%38.140.2%$97.65m
CVACCureVac NV -7.20%48.340.0%$67.53m
NVONovo Nordisk A/S -1.27%68.560.1%$53.56m
RGENRepligen Corp. -4.29%139.737.1%$52.11m
SNYSanofi -3.29%50.710.2%$47.43m
OPKOPKO Health, Inc. 0.16%3.1811.2%$47.39m

Company Profile

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.